Stock & Company Details
Ionis Pharmaceuticals Inc $IONS
Price:
N/A
N/A
166M
$7.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
-12.47
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
IONS technical indicators
Latest Ionis Pharmaceuticals Inc (IONS) indicator readings as of 2026-10-09.
IONS's 14-day RSI is 40.6, in neutral territory. At $45.28 it is trading 34.9% below its 200-day moving average of $69.52, and below its 50-day average of $52.81. Price sits in the middle of its Bollinger Bands ($41.48 to $48.67). ADX reads 43.8, indicating a trending market.
IONS backtested strategy results
How 4 rule-based strategies performed on Ionis Pharmaceuticals Inc (IONS) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +99.3% | 50% | 12 | -33.1% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +24.6% | 28% | 29 | -47.6% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +15.5% | 39% | 28 | -30.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +99.4% | 74% | 19 | -19.1% |
Overview
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Finance Bot
Ask your questions
Start by typing a question below.
